Announced today that it provides elevated $22 million in Series C equity funding.

‘We are grateful for the enthusiastic responses from investors inside our Series C funding round. It is a solid acknowledgement of the potential of ACD's technology, which has recently been featured in over 240 peer reviewed publications. The new financing will accelerate our pace of continued advancement and allow us to aggressively pursue our eyesight to bring RNAscope technologies to the forefront of accuracy medicine,’ stated Dr. Yuling Luo, Founder, President and CEO of ACD, ‘The company is now well-capitalized to realize this vision.’..

The scholarly study increases evidence that smoking is a major modifiable risk factor for MS, Dr. Myla Goldman, of the University of Virginia in Charlottesville, and Dr. Olaf Stuve, of the University of Texas Southwestern INFIRMARY at Dallas, wrote in an accompanying editorial. Most importantly, it provides the first proof, to our knowledge, that quitting smoking appears to delay onset of secondary progressive MS and provide protective benefit. Therefore, even after MS diagnosis, smoking can be a risk factor worthy of modifying, Goldman and Stuve wrote.The scholarly study increases evidence that smoking is a major modifiable risk factor for MS, Dr. Myla Goldman, of the University of Virginia in Charlottesville, and Dr. Olaf Stuve, of the University of Texas Southwestern INFIRMARY at Dallas, wrote in an accompanying editorial. Most importantly, it provides the first proof, to our knowledge, that quitting smoking appears to delay onset of secondary progressive MS and provide protective benefit. Therefore, even after MS diagnosis, smoking can be a risk factor worthy of modifying, Goldman and Stuve wrote.